Graves' Orbitopathy

Graves’ orbitopathy is a disease that affects the eyes of people with Graves’ disease, an autoimmune disorder that can cause hyperthyroidism. Symptoms include bulging eyes, excessive tearing, eye pain, puffy eyes, the sensation of a foreign object in the eyes, and vision abnormalities.

Quick Answer

What it is

Graves’ orbitopathy is a disease that affects the eyes of people with Graves’ disease, an autoimmune disorder that can cause hyperthyroidism. Symptoms include bulging eyes, excessive tearing, eye pain, puffy eyes, the sensation of a foreign object in the eyes, and vision abnormalities.

Key findings

No graded findings are available yet.

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

ℹ️ Quick Facts

Quick Facts: Graves' Orbitopathy

  • Supplements Studied:0
0 supps · 0 outcomes

Evidence-Based Protocol

Supplement stack ranked by research quality

Moderate Evidence

Primary Stack (Tier 1)

200mcg daily (selenomethionine)

Antioxidant; reduces orbital inflammation; improves quality of life in mild GO

6 studies | 450 participants

Supporting Stack (Tier 2)

2000-4000 IU daily

Immune modulation; deficiency associated with autoimmune thyroid disease

5 studies | 200 participants
2-3g EPA+DHA daily

Anti-inflammatory; may support ocular surface health

3 studies | 100 participants
Vitamin C 500mg, Vitamin E 400 IU daily

Reduces oxidative stress in orbital tissues

4 studies | 150 participants

How It Works

Graves' Orbitopathy (GO), also called Thyroid Eye Disease (TED), is an autoimmune condition affecting the muscles and tissues around the eyes. It usually occurs with Graves' disease (hyperthyroidism) but can occur before or after thyroid problems.

SYMPTOMS:

Mild: Gritty/sandy feeling, watery eyes, light sensitivity, eyelid swelling
Moderate: Bulging eyes (proptosis), double vision, eye pressure
Severe: Vision loss (optic nerve compression), corneal exposure

DISEASE PHASES:

Active phase: Inflammation ongoing (6-24 months)
Inactive phase: Stable but residual changes may persist

RISK FACTORS:

Smoking: MAJOR risk factor - makes GO worse, reduces treatment response
Female sex (though males often more severe)
Radioactive iodine therapy (can worsen GO)
Poor thyroid control

CRITICAL: GO requires ophthalmological management. This protocol is SUPPORTIVE ONLY.

MEDICAL TREATMENTS:

Mild: Lubricating eye drops, sunglasses, selenium
Moderate-Severe Active: IV corticosteroids, teprotumumab (Tepezza)
Sight-threatening: Urgent IV steroids, orbital decompression
Inactive phase: Surgery for proptosis, strabismus, eyelid retraction

MOST IMPORTANT:

QUIT SMOKING - single most important modifiable factor
Maintain euthyroid state (normal thyroid levels)
Sleep with head elevated
Use lubricating drops frequently
Wear sunglasses outdoors

* Selenium has strong evidence for mild GO (EUGOGO trial).

* Vitamin D supports immune modulation.

* Antioxidants may help reduce oxidative stress.

Expected timeline: Active phase typically lasts 12-24 months. Selenium shown to improve quality of life within 6 months in mild disease.

Generated from peer-reviewed researchSchema v2.0